Longevity & AgingUniXell Wins FDA and China Approval to Test Stem Cell Therapy for Parkinson's
UniXell Biotechnology has received Investigational New Drug clearance from the FDA for UX-DA003, a stem cell therapy designed to replace the dopamine-producing brain cells lost in Parkinson's disease. The therapy uses induced pluripotent stem cells — reprogrammed adult cells — to generate midbrain dopaminergic progenitors, the exact cell type that degenerates in Parkinson's. This FDA clearance follows a similar approval from China's drug regulator earlier in June 2026, allowing simultaneous clinical trials in both countries. Preclinical results reportedly show high cell purity, a dramatically lower required dose, and very low post-transplant cell growth, which the company says points to a safer profile. A related autologous version is already in a Phase I trial in China.
